Table 1 Description of study and participants. NR, not reported. *type of cancer diagnosis was only reported for 114 patients.
Clinical trial | % cancer patients in study | RCT design | Follow up | Primary outcome | Study participants | ||
|---|---|---|---|---|---|---|---|
Characteristic | DOAC | Comparator | |||||
ADAM VTE | 100% | Open label, superiority | 6 months | Major bleeding | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Apixaban 150 64, 48% male Lung 22% (32/150) 65% (96/150) 73% (108/150) | Dalteparin 150 64, 49% male Pancreatic 16% (24/150) 66% (97/150) 74% (110/150) |
Hokusai 2018 | 100% | Open label, non-inferiority | 12 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Edoxaban 522 64, 53% male Colorectal (16%) 53% (274/522) 72% (374/522) | Dalteparin 524 64, 50% male Colorectal (15%) 53% (280/524) 73% (383/524) |
SELECT-D | 100% | Open label, pilot trial | 6 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Rivaroxaban 203 67, 57% male Colorectal 27% (55/203) 58% (118/203) 69% (140/203) | Dalteparin 203 67, 48% male Colorectal 23% (47/203) 58% (118/203) 70% (142/203) |
Caravaggio | 100% | Open label, non-inferiority | 6 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Apixaban 576 67, 51% male Colorectal 21% (121/576) 68% (389/576) 61% (350/576) | Dalteparin 579 67, 48% male Colorectal 19% (113/579) 69% (396/579) 63% (350/579) |
Amplify | 2.5% | Double- blind, non-inferiority | 6 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Apixaban 88 66, 57% male Prostate %NR “approximately 1/3” NR | Warfarin 81 65, 61% male Prostate %NR “approximately 1/3” NR |
Hokusai 2013 | 2.5% | Double-blind, non-inferiority | 12 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Edoxaban 109 NR NR NR NR | Warfarin 99 NR NR NR NR |
RE-COVER I & II | 7.0% | Double-blind, double-dummy, non-inferiority | 6 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Dabigatran 173 63, 64% male Prostate 20% (23/114)* 9% (11/114)* NR | Warfarin 162 65, 62% male Prostate 21% (22/107)* 16% (17/107)* NR |
EINSTEIN DVT/PE | 7.2% | Open label, non-inferiority | 3–12 months | VTE recurrence | Drug Number patients Age, gender Most common cancer Metastatic cancer Anticancer therapy | Rivaroxaban 316 NR NR NR NR | Warfarin or acenocoumerol 281 NR NR NR NR |
